# Moderna

Source: https://onco.cc/companies/moderna/  
OnCo record `moderna` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Moderna is the mRNA company whose personalised cancer vaccine intismeran won the first phase 3 in the class (August 2026).

## Summary

Moderna, based in Cambridge, Massachusetts, and listed as MRNA, is the mRNA company whose personalised cancer vaccine intismeran autogene won the first phase 3 in its class in August 2026. Intismeran is developed with Merck and was first tested with pembrolizumab after melanoma surgery in KEYNOTE-942, and the pipeline includes mRNA-4359, a shared-antigen vaccine, plus in vivo CAR and other immuno-oncology mRNA programmes. OnCo links it to melanoma, to personalised neoantigen vaccines and self-amplifying RNA, to the Koch Institute and the Frederick National Laboratory, and to ideas on vaccines given only when a blood test turns positive and on automated manufacturing at commodity cost. Cold tumours and the immunosuppressive microenvironment are the bottleneck it confronts. Intismeran autogene has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Cambridge, MA
- Type: biotech
- Website: https://www.modernatx.com
- Ticker: MRNA

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Moderna
- Official website: https://www.modernatx.com

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/)
- trials: [A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07116616/), [An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN](https://onco.cc/trials/nct03897881/), [INTerpath-001 (V940-001)](https://onco.cc/trials/interpath-001/), [Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05533697/)
- companies: [Flagship Pioneering](https://onco.cc/companies/flagship-pioneering/)
- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [mRNA and lipid nanoparticle manufacturing](https://onco.cc/technologies/mrna-lnp-manufacturing/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/), [Self-amplifying and circular RNA therapeutics](https://onco.cc/technologies/self-amplifying-rna/)
- people: [Robert S. Langer](https://onco.cc/people/robert-langer/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/)
- ideas: [An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas](https://onco.cc/ideas/idea-prev-ebv-vaccine/), [Instruct tumour cells to make antibodies against their own oncoprotein](https://onco.cc/ideas/idea-bio1-mrna-intrabodies/), [mRNA-delivered MYC decoy proteins instead of MYC inhibitors](https://onco.cc/ideas/idea-bio1-omomyc-mrna/), [Personalised cancer vaccines at commodity cost through fully automated manufacturing](https://onco.cc/ideas/idea-moon-neoantigen-vaccines-at-scale/), [Personalised vaccines given only when the blood test turns positive](https://onco.cc/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/), [Vaccines aimed only at mutations shared by every tumour cell](https://onco.cc/ideas/idea-bio1-clonal-neoantigen-vaccines/)
- key papers: [KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery](https://onco.cc/key-papers/paper-keynote-942-lancet-2024/)
- institutions: [David H. Koch Institute for Integrative Cancer Research at MIT](https://onco.cc/institutions/mit-koch/), [Frederick National Laboratory for Cancer Research](https://onco.cc/institutions/frederick-national-lab/)

---
JSON: https://onco.cc/api/v1/entities/moderna.json